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Objectives: Bioﬁlms are microcolonies of bacteria in different metabolic stages,
imbedded in extracellular matrix, providing stability and antibiotic tolerance. This
mode of growth has been associated with chronic infections in CF, but not previously
for nontuberculous mycobacteria. We aim to examine if M. abscessus bioﬁlm
formation can take place in end stage CF lungs.
Methods: Explanted lungs from CF patients with chronic M. abscessus infection
were included. Diagnosis was made prior to transplantation (LTX) by repeated
culture and a reverse hybridization DNA assay (Inno LiPA). Histologic specimens
were stained using ﬂuorescence in situ hybridization with a speciﬁc peptide nucleic
acid probe (PNA-FISH) and examined with 3D confocal laser scanning microscopy
(CLSM), which was performed blinded with respect to infection status at time of
LTX. Clinical data were extracted from patient records.
Conclusion: Lungs from 5 patients with active (n = 4) or prior (n = 1) M. abscessus
were included. CLSM was accurate in determining the presence of M. abscessus
in 3/4 culture positive lungs. All received multidrug antimycobacterial treatment.
No mycobacteria were seen in the patient with resolved infection. M. abscessus
was found in sparse microcolonies, consistent with bioﬁlm growth, predominately
located in the respiratory zone of the lungs. The previously described cord formation
of roughM. abscessus variants (Sanchez-Chardi et al. J. Clin. Microbiol. 49:2293−5;
2011), may represent the same bioﬁlm growth phenomenon. This characteristic may
contribute to the disappointing results of antibiotic therapy for M. abscessus lung
infection.
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Mycobacterium abscessus (MAB) is well recognised as a pathogenic organism in
CF with a prevalence of up to 20%. Despite this, there is currently no consensus
on treatment. Recent work in non-CF bronchiectasis suggested successful treatment
of MAB could be completed using a regimen of an intravenous induction phase
followed by a prolonged course of at least 3 oral antibiotics. We have modiﬁed this
regimen and monitored treatment outcomes in our centre.
Methods:We completed a retrospective analysis of patients who received our MAB
therapy regimen.
Patients received 2 weeks of IV amikacin, meropenem and cefoxitin, followed by
a regimen of 3 oral antibiotics (a macrolide, quinolone, and a tetracycline) and
nebulised amikacin, for a minimum of 18 months and until they had 1 year of
negative cultures.
Results: 22 patients received treatment. Median time from ﬁrst isolation to
treatment was 329 days. During induction therapy, 32% had signiﬁcant nausea,
23% deranged renal function and 18% deranged liver function. 20 received full
maintenance therapy, 2 patients couldn’t tolerate oral medications and received
pulsed IV therapy. 19 patients have completed more than 6 months of maintenance
therapy of which 2 have been discontinued due to side effects. Of the remaining
17 patients, 15 (88%) have become culture negative for MAB. 7 patients have
completed therapy and remain culture negative (median follow-up 179 days).
Conclusions: This treatment regimen for MAB shows high levels of treatment
success which the majority of patients were able to tolerate. We recommend a
prospective clinical trial with alternative regimens to determine best practice in the
treatment of MAB infection in CF.
